Repositioning Candidates
Repositioning candidates for NAFLD are derived from DrugBank which fall into three categories: therapeutic strategy-associated, target-associated, and indication-associated candidates. For each candidate, detailed properties are extracted from DrugBank, and related strategies, target and NAFLD-associated disease in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
1608 records.
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R1601 | DB16620 | investigational | small molecule | Methopterin | Therapeutic strategy associated | Details |
| R1602 | DB16627 | approved; withdrawn | small molecule | Melphalan flufenamide | Therapeutic strategy associated | Details |
| R1603 | DB16629 | approved | small molecule | Serdexmethylphenidate | Therapeutic strategy associated | Details |
| R1604 | DB16648 | approved | biotech | Bacillus calmette-guerin substrain russian BCG-I live antigen | Therapeutic strategy associated | Details |
| R1605 | DB16665 | approved | biotech | Idecabtagene vicleucel | Target associated | Details |
| R1606 | DB16689 | investigational | biotech | Tengonermin | Therapeutic strategy associated | Details |
| R1607 | DB16697 | investigational | biotech | Glutazumab | Target associated | Details |
| R1608 | DB16703 | approved; investigational | small molecule | Belumosudil | Therapeutic strategy associated | Details |